Abstract
Juvenile idiopathic arthritis is one of the most common chronic connective tissue diseases in children.JIA patients have shown sustained and significant improvement after being treated by biological agents.To systematically review the clinical efficacy and safety of biological agents in JIA, we searched the related literatures, focusing on randomized controlled trials (RCT). Current evidence shows that for JIA patients who have an inadequate response to conventional treatment, a short-term improvement could be achieved when they are treated with biologics.TNF-α blockers and CD80 antagonist shows clinic efficacy and safety in treating poliarticular course JIA(pJIA); IL-6 receptor antagonist and IL-1 blockers shows clinic efficacy and safety in treating systemic JIA(sJIA). Key words: Juvenile idiopathic arthritis; Biological agents; Efficacy; Safety
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
